Arca
Skip to content
Tools
Tools

Overactive bladder

Drug research and approvals for overactive bladder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 77 studies of overactive bladder are recruiting on ClinicalTrials.gov, Health Canada has authorized 13 drug trials for it since 2013, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 77
  • Trials authorized in Canada: 13
  • FDA orphan approvals: 0
  • EU medicines: 3

Recruiting Now

Newest start dates first, of 77 recruiting on ClinicalTrials.gov ↗

How Its Trials Ended

794 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 188 whose ending is known, 51% met their primary endpoint, 2% missed it and 47% stopped early.

  • Completed, result not reported38649%
  • Status unknown11314%
  • Ongoing10713%
  • Met its primary endpoint9612%
  • Stopped: other or unclear405%
  • Stopped: enrollment or feasibility304%
  • Stopped: lack of efficacy61%
  • Stopped: sponsor or business decision51%
  • Missed its primary endpoint41%
  • Stopped: safety41%
  • Stopped: funding30%

Trials Authorized in Canada

The 10 newest of 13; search them all in Canada trials
Aug 19, 2020A phase 3,double-blind,randomized,multicentre,parallel group,placebo-controlled sequential dose titration study to evaluate efficacy, safety and…MirabegronAstellas PharmaClosed
Apr 17, 2019A phase 3 double-blind, randomized, placebo-controlled, multi-center study to evaluate the efficacy, safety and tolerability of vibegron in men with overactive…Vibegron (RVT-901)Urovant Sciences GmbHClosed
Oct 5, 2018A phase 2, multicenter, randomized, double-blind, placebo-controlled, single-treatment, 2-stage, dose-finding study evaluating the efficacy and safety of botox…BotoxAbbVieClosed
Apr 20, 2018An international phase 3, randomized, double-blind, active (tolterodine)-controlled multicenter extension study to evaluate the long-term safety and efficacy…Vibegron (RVT-901, MK-4618)Urovant Sciences GmbHOngoing
Apr 20, 2018An international phase 3, randomized, double-blind, placebo- and active (tolterodine)-controlled multicenter study to evaluate the safety and efficacy of…Vibegron (RVT-901, MK-4618)Urovant Sciences GmbHClosed
Nov 5, 2015A study to compare the effect of fesotrodine 4mg and 8mg and oxybutynin 5mg twice daily after steady state dosing versus placebo in subjects over age of 75…Fesoterodine-oxybutyninGovernors Of The University Of AlbertaClosed
Oct 20, 2015Randomized cross-over study of fesoterodine on urgency episodes in parkinson's disease population.FesoterodineDr. Lysanne CampeauPending
Aug 18, 2015Efficacité et tolérabilité de la fésotérodine chez les enfants atteints de vessie hyperactive: phase d¿extension.FesoterodineChu De QuéBec-Université LavalOngoing
Dec 17, 2014A phase 4, double-blind, randomized, placebo-controlled, parallel group, multi-center study to evaluate the efficacy, safety, and tolerability of mirabegron in…Myrbetriq (mirabegron)Astellas PharmaClosed
Sep 18, 2014Efficiency and tolerance of fesoterodin and oxybutynin in children with a hyperactive bladder: a comparative studyfesoterodine/ oxybutyninCentre Hospitalier De L’Université LavalOngoing

Medicines Authorised in the EU

Newest first
Jun 27, 2024ObgemsaVibegronPierre Fabre MedicamentEMA ↗
Dec 20, 2012BetmigaMirabegronAstellas Pharma Europe B.V.EMA ↗
Oct 22, 2004EmselexDarifenacin hydrobromidepharmaand GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.